Engineered bacteria delivering TNF-targeting RNA interference induce transcriptional reprogramming in inflammatory bowel disease
Ontology highlight
ABSTRACT: Tumor necrosis factor (TNF) is a key regulator of inflammatory signaling in inflammatory bowel disease (IBD). Although anti-TNF therapies appear effective in clinical trials, their clinical use is limited by poor response rates and safety concerns. We previously developed an engineered Escherichia coli-based delivery system that effectively silences intracellular TNF and demonstrated its therapeutic potential in a dextran sodium sulfate (DSS)-induced preclinical colitis model. In this study, we evaluated the biological effects of this system by performing bulk RNA sequencing to characterize the transcriptomic response in colonic tissue upon bacterium-mediated TNF silencing in mice. We conducted differential gene expression analysis, multidimensional scaling, and pathway enrichment analyses. We found that DSS-induced colitis was associated with strong activation of inflammatory and cytokine-driven transcriptional programs in controls. Conversely, bacterial therapy-induced TNF silencing led to coordinated transcriptional reprogramming, characterized by suppressed immune signaling pathways and partial restoration of epithelial gene expression. These findings demonstrate that engineered bacterial RNA interference enables disease-specific transcriptional reprogramming, highlighting its potential as a valuable biotechnological platform for improving IBD treatments.
ORGANISM(S): Mus musculus
PROVIDER: GSE332718 | GEO | 2026/09/30
REPOSITORIES: GEO
ACCESS DATA